115 related articles for article (PubMed ID: 38225203)
1. Molecular prognostic of nine parthanatos death-related genes in glioma, particularly in COL8A1 identification.
Fan S; Li H; Liu K
J Neurochem; 2024 Mar; 168(3):205-223. PubMed ID: 38225203
[TBL] [Abstract][Full Text] [Related]
2. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
[TBL] [Abstract][Full Text] [Related]
3. Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X
Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657
[TBL] [Abstract][Full Text] [Related]
4. COL8A1 is a potential prognostic biomarker associated with migration, proliferation, and tumor microenvironment in glioma.
Liu M; Liang W; Su Y; Wen Y; Qi J; Wang L; Su S; Zhao J; Shan J; Wang J
Exp Cell Res; 2024 May; 439(1):114076. PubMed ID: 38719174
[TBL] [Abstract][Full Text] [Related]
5. A novel peroxisome-related gene signature predicts clinical prognosis and is associated with immune microenvironment in low-grade glioma.
Gao D; Zhou Q; Hou D; Zhang X; Ge Y; Zhu Q; Yin J; Qi X; Liu Y; Lou M; Zhou L; Bi Y
PeerJ; 2024; 12():e16874. PubMed ID: 38406287
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Fibroblast-Related Prognostic Model in Glioma Based on Bioinformatics Methods.
Zhang H; Huang Y; Yang E; Gao X; Zou P; Sun J; Tian Z; Bao M; Liao D; Ge J; Yang Q; Li X; Zhang Z; Luo P; Jiang X
Biomolecules; 2022 Oct; 12(11):. PubMed ID: 36358948
[TBL] [Abstract][Full Text] [Related]
7. Elucidating the impact of parthanatos-related microRNAs on the tumoral immune microenvironment and clinical outcome in low-grade gliomas.
Zhu P; Wu H; Zheng B; Wang H; Zou Y
Discov Oncol; 2024 May; 15(1):153. PubMed ID: 38730061
[TBL] [Abstract][Full Text] [Related]
8. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
9. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
10.
Chen Z; Cui S; Dai Y; Lu C; Zhang H; Zhao W; Yan H; Zhang Y
Oxid Med Cell Longev; 2022; 2022():7595230. PubMed ID: 36193074
[TBL] [Abstract][Full Text] [Related]
11. Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
Tu Z; Ji Q; Han Q; Long X; Li J; Wu L; Huang K; Zhu X
BMC Cancer; 2022 Sep; 22(1):973. PubMed ID: 36096781
[TBL] [Abstract][Full Text] [Related]
12. The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
Wang W; Lu Z; Wang M; Liu Z; Wu B; Yang C; Huan H; Gong P
Front Immunol; 2022; 13():998236. PubMed ID: 36110851
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Gene Expression Signature in Patients With Distinct Glioma Grades.
Ait Ssi S; Chraa D; El Azhary K; Sahraoui S; Olive D; Badou A
Front Immunol; 2021; 12():685213. PubMed ID: 34539626
[TBL] [Abstract][Full Text] [Related]
14. Molecular subtypes based on centrosome-related genes can predict prognosis and therapeutic responsiveness in patients with low-grade gliomas.
Zhang G; Tai P; Fang J; Chen A; Chen X; Cao K
Front Oncol; 2023; 13():1157115. PubMed ID: 37051542
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
16. A Human Adenovirus C Infection-Related Gene Panel for Predicting Survival and Treatment Responsiveness in Glioma Patients.
Wu M; Shi Y; Liu Y; Li Z; Wu H; Yu Z; Wang Z; Xu C
World Neurosurg; 2024 Mar; 183():e173-e186. PubMed ID: 38097166
[TBL] [Abstract][Full Text] [Related]
17. Construction of a novel molecular typing and scoring system for anoikis distinguishes between different prognostic risks and treatment responsiveness in low-grade glioma.
Zhang G; Chen A; Fang J; Wu A; Chen G; Tai P; Chen H; Chen X; Cao K
Front Immunol; 2023; 14():1105210. PubMed ID: 37114037
[TBL] [Abstract][Full Text] [Related]
18. Identification of prognostic biomarkers for cervical cancer based on programmed cell death-related genes and assessment of their immune profile and response to drug therapy.
Feng S; Wang Z; Zhang H; Hou B; Xu Y; Hao S; Lu Y
J Gene Med; 2024 Jan; 26(1):e3643. PubMed ID: 38044747
[TBL] [Abstract][Full Text] [Related]
19. A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma.
Liu W; Zou J; Ren R; Liu J; Zhang G; Wang M
Technol Cancer Res Treat; 2021; 20():1533033821992084. PubMed ID: 33550903
[TBL] [Abstract][Full Text] [Related]
20. Characterization of DNA Damage Repair Related Signature and Molecular Feature in Low-Grade Gliomas to Aid Chemotherapy and Drug Discovery.
Yin X; Li M; He Z
Front Biosci (Landmark Ed); 2023 Oct; 28(10):234. PubMed ID: 37919061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]